Cerus Corporation (CERS)

1.7100 +0.0100 (+0.59%) 收市：04:00PM EDT

Cerus Corporation

1220 Concord Avenue
Suite 600
Concord, CA 94520
United States
925 288 6000
https://www.cerus.com

版塊: Healthcare
行業: Medical Devices
全職員工: 625

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. William M. Greenman	President, CEO & Director	1.33M	627k	1967
Mr. Kevin D. Green	VP of Finance & CFO	748.49k	無	1972
Mr. Vivek K. Jayaraman	Chief Operating Officer	861.67k	無	1975
Ms. Chrystal Jensen	Chief Legal Officer & General Counsel	692.16k	無	1971
Dr. Richard J. Benjamin MBChB, Ph.D.	Chief Medical Officer	719.74k	無	1960
Dr. Laurence M. Corash	Co-Founder & Chief Scientific Officer	697.77k	191.79k	1944
Ms. Lori L. Roll	VP of Administration & Corporate Secretary	無	無	無
Mr. Matthew M. Notarianni	Senior Director of Investor Relations	無	無	無
Lainie Corten	Vice President of Global Marketing	無	無	無
Ms. Alicia Goodman	Chief Human Resources Officer	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

公司管治

截至 2024年4月1日 止，Cerus Corporation 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：6；董事會：3；股東權利：7；現金賠償：5。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。